Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17497191 | 1.00 | PPARG (0.48) | PPARGEPHX2PPARACYP1A2KMT2A | |
| SCHEMBL9007628 | 0.84 | CYP1A2 (0.68) | CYP1A2MMECPA1CPA3 | |
| SCHEMBL629350 | 0.84 | CYP1A2 (0.68) | CYP1A2MMECPA1CPA3 | |
| SCHEMBL252900 | 0.84 | CYP1A2 (0.68) | CYP1A2MMECPA1CPA3 | |
| SCHEMBL4663230 | 0.84 | CYP1A2 (0.65) | PPARGEPHX2PPARACYP1A2KMT2A | |
| SCHEMBL6005266 | 0.83 | KMO (0.48) | PPARGPPARACYP1A2KMT2AGRIK1 | |
| SCHEMBL6005075 | 0.83 | KMO (0.48) | PPARGPPARACYP1A2KMT2AGRIK1 | |
| SCHEMBL5887996 | 0.81 | PPARG (0.49) | PPARGEPHX2PPARACYP1A2KMT2A | |
| SCHEMBL5887992 | 0.81 | PPARG (0.49) | PPARGEPHX2PPARACYP1A2KMT2A | |
| SCHEMBL14041569 | 0.80 | SLC6A2 (0.42) | PPARGEPHX2PPARAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046590-A1 | SONIC HEDGEHOG MODULATORS | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-02-18 | — | — | US | disclosed |
| US-5965562-A | TREATING DISORDERS INDUCED BY SUBSTANCE P AND MIGRAINE HEADACHE | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0707006-B1 | Aroyl-piperidine derivatives | NOVARTIS AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| EP-0707006-A1 | Aroyl-piperidine derivatives | CIBA-GEIGY AG (CH) | 1996-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046590-A1 | SONIC HEDGEHOG MODULATORS | SHH, GLI1, SMO | PPARG 1902/4885EPHX2 1721/4885PPARA 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.